News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Iframe sync Post Navigation Previous Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext Major shareholder announcement – BlackRock, Inc. More Stories Cancer Clinical Trial Diagnostics Healthcare News Pharmaceutical New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer Staff May 31, 2025 Cancer Clinical Trial COVID-19 Epidemics Healthcare immunotherapy Medicaid Medicare Melanoma News Pharmaceutical Pregnancy Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing Staff May 31, 2025 Cancer Clinical Trial COVID-19 Healthcare News Pharmaceutical Vaccine Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer Staff May 31, 2025
